These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 23775258)

  • 1. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
    Pennell DJ; Udelson JE; Arai AE; Bozkurt B; Cohen AR; Galanello R; Hoffman TM; Kiernan MS; Lerakis S; Piga A; Porter JB; Walker JM; Wood J;
    Circulation; 2013 Jul; 128(3):281-308. PubMed ID: 23775258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Pibiri M; Nair SV; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2008 Feb; 10(1):12. PubMed ID: 18298856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
    J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
    Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
    Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.
    Alpendurada F; Smith GC; Carpenter JP; Nair SV; Tanner MA; Banya W; Dessi C; Galanello R; Walker JM; Pennell DJ
    J Cardiovasc Magn Reson; 2012 Jan; 14(1):8. PubMed ID: 22277065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
    Hagag AA; Hamam MA; Taha OA; Hazaa SM
    Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.
    Smith GC; Alpendurada F; Carpenter JP; Alam MH; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Westwood MA; Galanello R; Roughton M; Pennell DJ
    J Cardiovasc Magn Reson; 2011 Jul; 13(1):34. PubMed ID: 21733147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
    Pennell DJ; Berdoukas V; Karagiorga M; Ladis V; Piga A; Aessopos A; Gotsis ED; Tanner MA; Smith GC; Westwood MA; Wonke B; Galanello R
    Blood; 2006 May; 107(9):3738-44. PubMed ID: 16352815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.
    Pennell DJ; Carpenter JP; Roughton M; Cabantchik Z
    J Cardiovasc Magn Reson; 2011 Sep; 13(1):45. PubMed ID: 21910880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T2* magnetic resonance and myocardial iron in thalassemia.
    Pennell DJ
    Ann N Y Acad Sci; 2005; 1054():373-8. PubMed ID: 16339685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.